Prelude Therapeutics Inc
PRLD2.290USD
+0.150+7.01%
Market hours （ET）Quotes delayed by 15 min
129.61MMarket Cap
LossP/E TTM
More Details of Prelude Therapeutics Inc Company
Prelude Therapeutics Incorporated is a clinical-stage fully integrated oncology company built on a foundation of drug discovery to deliver novel precision cancer medicines to underserved patients. It has developed a diverse pipeline consisting of multiple distinct programs: kinases, targeted protein degraders, and precision antibody drug conjugates. Its product candidates include PRT3789, PRT2527 and PRT7732. PRT3789 is a highly selective degrader of SMARCA2 protein, which, along with SMARCA4, controls gene regulation through chromatin remodeling. Its CDK9 program is an essential regulator of cancer-promoting transcriptional programs, including those driven by MCL1, MYC and MYB. PRT2527 is designed to be a potent and selective CDK9 inhibitor that has the potential to avoid off-target toxicities observed with other less selective CDK9 inhibitor. PRT7732 is a highly selective and orally bioavailable SMARCA2 degrader.
Prelude Therapeutics Inc Info
Ticker SymbolPRLD
Company namePrelude Therapeutics Inc
IPO dateSep 25, 2020
CEOVaddi (Krishna)
Number of employees131
Security typeOrdinary Share
Fiscal year-endSep 25
Address175 Innovation Boulevard
CityWILMINGTON
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryUnited States of America
Postal code19805
Phone13024671280
Websitehttps://preludetx.com/
Ticker SymbolPRLD
IPO dateSep 25, 2020
CEOVaddi (Krishna)
Company Executives of Prelude Therapeutics Inc
Name
Name/Position
Position
Shareholding
Change
Dr. Krishna (Kris) Vaddi, Ph.D.
Dr. Krishna (Kris) Vaddi, Ph.D.
Chief Executive Officer, Founder, Director
Chief Executive Officer, Founder, Director
3.67M
+29.33%
Dr. Paul A. Friedman, M.D.
Dr. Paul A. Friedman, M.D.
Independent Chairman of the Board
Independent Chairman of the Board
500.10K
--
Dr. Andrew P. Combs, Ph.D.
Dr. Andrew P. Combs, Ph.D.
Chief Chemistry Officer
Chief Chemistry Officer
480.12K
+27.99%
Dr. Peggy A. Scherle, Ph.D.
Dr. Peggy A. Scherle, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
185.69K
+2.77%
Ms. Katina Dorton
Ms. Katina Dorton
Director
Director
--
--
Dr. Paul Scherer, M.D.
Dr. Paul Scherer, M.D.
Independent Director
Independent Director
--
--
Dr. Victor Sandor, M.D.
Dr. Victor Sandor, M.D.
Independent Director
Independent Director
--
--
Mr. Bryant D. Lim, J.D.
Mr. Bryant D. Lim, J.D.
Chief Financial Officer, Chief Legal Officer, Corporate Secretary
Chief Financial Officer, Chief Legal Officer, Corporate Secretary
--
--
Dr. David P. Bonita, M.D.
Dr. David P. Bonita, M.D.
Independent Director
Independent Director
--
--
Mr. Martin Babler
Mr. Martin Babler
Independent Director
Independent Director
--
--
Name
Name/Position
Position
Shareholding
Change
Dr. Krishna (Kris) Vaddi, Ph.D.
Dr. Krishna (Kris) Vaddi, Ph.D.
Chief Executive Officer, Founder, Director
Chief Executive Officer, Founder, Director
3.67M
+29.33%
Dr. Paul A. Friedman, M.D.
Dr. Paul A. Friedman, M.D.
Independent Chairman of the Board
Independent Chairman of the Board
500.10K
--
Dr. Andrew P. Combs, Ph.D.
Dr. Andrew P. Combs, Ph.D.
Chief Chemistry Officer
Chief Chemistry Officer
480.12K
+27.99%
Dr. Peggy A. Scherle, Ph.D.
Dr. Peggy A. Scherle, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
185.69K
+2.77%
Ms. Katina Dorton
Ms. Katina Dorton
Director
Director
--
--
Dr. Paul Scherer, M.D.
Dr. Paul Scherer, M.D.
Independent Director
Independent Director
--
--
Revenue Breakdown
Relevant data have not been disclosed by the company yet.
Relevant data have not been disclosed by the company yet.
By Business
By Region
Relevant data have not been disclosed by the company yet.
Shareholding Stats
Updated: Sun, Nov 16
Updated: Sun, Nov 16
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
OrbiMed Advisors, LLC
21.81%
Baker Bros. Advisors LP
20.24%
Vaddi (Krishna)
7.34%
Millennium Management LLC
2.29%
The Vanguard Group, Inc.
1.99%
Other
46.33%
Shareholders
Shareholders
Proportion
OrbiMed Advisors, LLC
21.81%
Baker Bros. Advisors LP
20.24%
Vaddi (Krishna)
7.34%
Millennium Management LLC
2.29%
The Vanguard Group, Inc.
1.99%
Other
46.33%
Shareholder Types
Shareholders
Proportion
Hedge Fund
24.74%
Private Equity
21.81%
Individual Investor
9.93%
Investment Advisor
5.64%
Investment Advisor/Hedge Fund
1.94%
Research Firm
0.32%
Venture Capital
0.03%
Other
35.59%
Institutional Shareholding
Updated: Wed, Oct 1
Updated: Wed, Oct 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q3
152
27.28M
62.37%
-14.64M
2025Q2
158
35.20M
80.72%
-13.66M
2025Q1
169
35.41M
81.20%
-13.64M
2024Q4
176
41.97M
99.49%
-4.74M
2024Q3
176
39.67M
94.09%
-11.21M
2024Q2
173
43.50M
103.37%
-2.47M
2024Q1
184
38.12M
90.60%
-8.41M
2023Q4
190
38.61M
71.39%
-9.45M
2023Q3
202
40.53M
76.60%
-4.90M
2023Q2
201
43.54M
105.11%
+2.58M
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
OrbiMed Advisors, LLC
10.91M
24.94%
--
--
Jun 30, 2025
Baker Bros. Advisors LP
10.12M
23.14%
--
--
Jun 30, 2025
Vaddi (Krishna)
3.67M
8.39%
+832.02K
+29.33%
Mar 31, 2025
Millennium Management LLC
248.42K
0.57%
+101.65K
+69.26%
Jun 30, 2025
The Vanguard Group, Inc.
932.57K
2.13%
-76.63K
-7.59%
Jun 30, 2025
T. Rowe Price Associates, Inc.
914.94K
2.09%
-44.36K
-4.62%
Jun 30, 2025
Renaissance Technologies LLC
581.80K
1.33%
-74.90K
-11.41%
Jun 30, 2025
Acadian Asset Management LLC
540.57K
1.24%
+11.24K
+2.12%
Jun 30, 2025
Friedman (Paul A)
500.10K
1.14%
--
--
Mar 31, 2025
Combs (Andrew P)
480.12K
1.1%
+105.00K
+27.99%
Mar 31, 2025
View more
Related ETFs
Updated: Sat, Dec 6
Updated: Sat, Dec 6
Name
Proportion
Global X Russell 2000 Covered Call ETF
0%
ProShares UltraPro Russell2000
0%
Dimensional US Core Equity 1 ETF
0%
iShares Micro-Cap ETF
0%
iShares Russell 2000 Value ETF
0%
Global X Russell 2000 ETF
0%
Schwab U.S. Small-Cap ETF
0%
Proshares Ultra Russell 2000
0%
iShares Russell 2000 ETF
0%
Schwab U.S. Broad Market ETF
0%
View more
Global X Russell 2000 Covered Call ETF
Proportion0%
ProShares UltraPro Russell2000
Proportion0%
Dimensional US Core Equity 1 ETF
Proportion0%
iShares Micro-Cap ETF
Proportion0%
iShares Russell 2000 Value ETF
Proportion0%
Global X Russell 2000 ETF
Proportion0%
Schwab U.S. Small-Cap ETF
Proportion0%
Proshares Ultra Russell 2000
Proportion0%
iShares Russell 2000 ETF
Proportion0%
Schwab U.S. Broad Market ETF
Proportion0%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data
FAQs
Who are the top five shareholders of Prelude Therapeutics Inc?
The top five shareholders of Prelude Therapeutics Inc are:
OrbiMed Advisors, LLC holds 10.91M shares, accounting for 24.94% of the total shares.
Baker Bros. Advisors LP holds 10.12M shares, accounting for 23.14% of the total shares.
Vaddi (Krishna) holds 3.67M shares, accounting for 8.39% of the total shares.
Millennium Management LLC holds 248.42K shares, accounting for 0.57% of the total shares.
The Vanguard Group, Inc. holds 932.57K shares, accounting for 2.13% of the total shares.
OrbiMed Advisors, LLC holds 10.91M shares, accounting for 24.94% of the total shares.
Baker Bros. Advisors LP holds 10.12M shares, accounting for 23.14% of the total shares.
Vaddi (Krishna) holds 3.67M shares, accounting for 8.39% of the total shares.
Millennium Management LLC holds 248.42K shares, accounting for 0.57% of the total shares.
The Vanguard Group, Inc. holds 932.57K shares, accounting for 2.13% of the total shares.
What are the top three shareholder types of Prelude Therapeutics Inc?
The top three shareholder types of Prelude Therapeutics Inc are:
OrbiMed Advisors, LLC
Baker Bros. Advisors LP
Vaddi (Krishna)
OrbiMed Advisors, LLC
Baker Bros. Advisors LP
Vaddi (Krishna)
How many institutions hold shares of Prelude Therapeutics Inc (PRLD)?
As of 2025Q3, 152 institutions hold shares of Prelude Therapeutics Inc, with a combined market value of approximately 27.28M, accounting for 62.37% of the total shares. Compared to 2025Q2, institutional shareholding has increased by -18.36%.
What is the biggest source of revenue for Prelude Therapeutics Inc?
In --, the -- business generated the highest revenue for Prelude Therapeutics Inc, amounting to -- and accounting for --% of total revenue.
